Updated:
Marker Therapeutics
Marker Therapeutics is a Houston-based clinical-stage biotech developing multi-antigen specific T-cell therapies for solid tumors, led by CEO Peter L.
Marker Therapeutics
Marker Therapeutics was founded in 1993 and is led by Peter L. Hoang, who has served as CEO since 2022. The company originated from the Baylor College of Medicine and focused on cell therapy development, with a lineage tracing back to academic research in adoptive T-cell transfer. Marker operates as a publicly traded entity (NASDAQ: MRKR) and has not disclosed a founding family or wealth origin. The firm's strategy centers on developing non-viral, multi-antigen specific T-cell therapies that target solid tumors through the body's natural T-cell response. Marker's pipeline includes MT-601 for non-Hodgkin lymphoma, MT-401 for acute myeloid leukemia, and MT-302 for multiple solid tumors. The company has collaborated with institutions such as the Baylor College of Medicine and has secured funding through public offerings and partnerships. Deployment remains early-stage, with Marker's market capitalization hovering around $5-10 million as of 2025 (per public filings). The company employs a small team of scientists and clinicians in Houston, supporting a lean R&D operation. Adjacent structures include academic licensing agreements with Baylor College of Medicine and the Texas Children's Hospital. In 2024, Marker reported positive early data from its Phase 1 lymphoma trial (per company press release, 2024). Marker's structural differentiator lies in its multi-antigen specific T-cell platform, which uses multi-primed T-cells to recognize five tumor-associated antigens without genetic modification. This differs from CAR-T and TCR approaches, potentially reducing toxicity while targeting tumor heterogeneity. The company's clinical strategy focuses on cancers with high unmet need, including acute myeloid leukemia and pancreatic cancer.
General information
Firm type
Asset Manager
Year founded
1993
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Houston
Corporate office
Houston, TX, United States
Principals
Peter L. Hoang
President & Chief Executive Officer
Juan F. Vera
Chief Scientific Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Marker Therapeutics?
Peter L. Hoang has served as President and Chief Executive Officer since 2022 and leads corporate strategy and investment decisions. The company's board, including Chairman John P. T. Vander, oversees major capital allocation and clinical program prioritization (per Marker SEC filings, 2024).
How does Marker Therapeutics source its technology and partnerships?
Marker's technology originated from Baylor College of Medicine, where its multi-antigen specific T-cell platform was developed. The firm holds exclusive licenses from Baylor and Texas Children's Hospital. Marker collaborates with academic institutions for clinical trials and receives research funding through federal grants and partnerships (per company annual report, 2023).
Is Marker Therapeutics structured as a single family office or as a public biotech?
Marker Therapeutics is a publicly traded biotechnology company listed on the NASDAQ under the ticker MRKR. It operates as a clinical-stage biopharmaceutical firm focused on oncology drug development, not as a family office or investment vehicle.
What investment stages does Marker Therapeutics target?
Marker Therapeutics operates as a development-stage biotech, focusing on preclinical and clinical-stage assets. Its primary capital allocation is directed toward clinical trials, manufacturing scale-up, and regulatory activities for its T-cell therapy pipeline. The firm does not make external investments or participate in syndicated venture deals.
Which sectors does Marker Therapeutics explicitly avoid?
Marker Therapeutics is exclusively focused on oncology and immunotherapy. It does not invest in other biotech areas such as infectious disease, rare genetic disorders, or non-oncology autoimmune conditions (per company pipeline disclosures, 2024).
How is Marker Therapeutics related to Baylor College of Medicine?
Marker was spun out from Baylor College of Medicine, where its T-cell technology was initially developed. The company maintains a close relationship through licensing agreements and ongoing research collaborations with Baylor and the Texas Children's Hospital. Marker's chief scientific officer, Juan F. Vera, previously held a faculty position at Baylor (per company filings, 2023).
Where does Marker Therapeutics' funding come from?
Marker Therapeutics has historically raised capital through public equity offerings, including a $10 million offering in 2023. The company also receives non-dilutive funding through federal grants from the National Cancer Institute and other agencies. As a publicly traded company, it does not have disclosed family-office backing or single institutional anchor (per SEC filings, 2024).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: